EMEA-001441-PIP02-15-M02

Key facts

Active substance
semaglutide
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0197/2019
PIP number
EMEA-001441-PIP02-15-M02
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Novo Nordisk

Tel. +45 44448888
E-mail: paediatrics@novonordisk.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating